Da Xu

4.5k total citations · 1 hit paper
71 papers, 2.1k citations indexed

About

Da Xu is a scholar working on Oncology, Molecular Biology and Hepatology. According to data from OpenAlex, Da Xu has authored 71 papers receiving a total of 2.1k indexed citations (citations by other indexed papers that have themselves been cited), including 33 papers in Oncology, 25 papers in Molecular Biology and 23 papers in Hepatology. Recurrent topics in Da Xu's work include Hepatocellular Carcinoma Treatment and Prognosis (22 papers), Colorectal Cancer Treatments and Studies (12 papers) and Ferroptosis and cancer prognosis (10 papers). Da Xu is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (22 papers), Colorectal Cancer Treatments and Studies (12 papers) and Ferroptosis and cancer prognosis (10 papers). Da Xu collaborates with scholars based in China, Ethiopia and United States. Da Xu's co-authors include Ying Zhu, Qiongzhu Dong, Ze Zhang, Baocai Xing, Yan Zheng, Lun–Xiu Qin, Kun Wang, Lu Lu, Peijun Zhou and Hu‐Liang Jia and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and The Journal of Immunology.

In The Last Decade

Da Xu

68 papers receiving 2.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Disruption of tumour-associated macrophage trafficking by the osteopontin-induced colony-stimulating factor-1 signalling sensitises hepatocellular carcinoma to anti-PD-L1 blockade

2019 333 citations Ying Zhu, Da Xu et al. Gut profile →

Peers

Countries citing papers authored by Da Xu

Since Specialization

Citations

This map shows the geographic impact of Da Xu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Da Xu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Da Xu more than expected).

Fields of papers citing papers by Da Xu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Da Xu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Da Xu. The network helps show where Da Xu may publish in the future.

Co-authorship network of co-authors of Da Xu

This figure shows the co-authorship network connecting the top 25 collaborators of Da Xu. A scholar is included among the top collaborators of Da Xu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Da Xu. Da Xu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Disruption of MerTK increases the efficacy of checkpoint inhibitor by enhancing ferroptosis and immune response in hepatocellular carcinoma 2024 ·Cell Reports Medicine ·Shun Wang, (unknown), (unknown), (unknown), Yan Zheng, Da Xu, (unknown), Ze Zhang, Yan Fu, Hao Wang, Xufeng Wang, Tiantian Zou, Xiaotian Shen, Lumin Zhang, (unknown), Lu Lu, Lun–Xiu Qin, Qiongzhu Dong	42
2	Ti-Mo microalloyed medium Mn steels: Precipitation and strengthening mechanism 2024 ·Materials Science and Engineering A ·(unknown), (unknown), (unknown), Da Xu, (unknown), Nan Xiao, Minghui Cai, Young‐Kook Lee	7
3	Preoperative neoadjuvant targeted therapy remodels intra-tumoral heterogeneity of clear-cell renal cell carcinoma and ferroptosis inhibition induces resistance progression 2024 ·Cancer Letters ·Wenjin Chen, Xiuwu Pan, (unknown), (unknown), Da Xu, Jiaxin Chen, Keqin Dong, (unknown), Jianqing Ye, Sishun Gan, Linhui Wang, Zhou Wang, Xingang Cui	16
4	Five‐year survival post hepatectomy for colorectal liver metastases in a real‐world Chinese cohort: Recurrence patterns and prediction for potential cure 2023 ·Cancer Medicine ·(unknown), (unknown), Xiaoluan Yan, (unknown), (unknown), Hongwei Wang, Kemin Jin, Quan Bao, (unknown), (unknown), Da Xu, Baocai Xing	14
5	Targeting the TCA cycle through cuproptosis confers synthetic lethality on ARID1A-deficient hepatocellular carcinoma 2023 ·Cell Reports Medicine ·Tao Xing, Li Li, Yiran Chen, Gaoda Ju, Guilan Li, Xiaoyun Zhu, Yubo Ren, Jing Zhao, (unknown), Yan Li, Da Xu, Jun Liang	40
6	Heterogeneity of tumor microenvironment is associated with clinical prognosis of non-clear cell renal cell carcinoma: a single-cell genomics study 2022 ·Cell Death and Disease ·Wenjin Chen, Hao Cao, Jianwei Cao, Li Zuo, Fajun Qu, Da Xu, Hao Zhang, Haiyi Gong, Jiaxin Chen, Jianqing Ye, Sishun Gan, Zhou Wang, Dawei Zhu, Xiuwu Pan, Xingang Cui	14
7	Development of a model to predict pathologic response to chemotherapy in patients with colorectal liver metastases 2021 ·Journal of Gastrointestinal Oncology ·Da Xu, Yanyan Wang, Xiaoluan Yan, Juan Li, Kun Wang, Baocai Xing	10
8	USP39 promotes malignant proliferation and angiogenesis of renal cell carcinoma by inhibiting VEGF-A165b alternative splicing via regulating SRSF1 and SRPK1 2021 ·Cancer Cell International ·Xiuwu Pan, Da Xu, Wenjin Chen, Jiaxin Chen, Weijie Chen, Jianqing Ye, Sishun Gan, Zhou Wang, Song Xu, Lei Shi, Xingang Cui	18
9	Identification and integrative analysis of ACLY and related gene panels associated with immune microenvironment reveal prognostic significance in hepatocellular carcinoma 2021 ·Cancer Cell International ·Yunfeng Xu, Ze Zhang, Da Xu, Xin Yang, Lina Zhou, Ying Zhu	15
10	TRIM47 promotes malignant progression of renal cell carcinoma by degrading P53 through ubiquitination 2021 ·Cancer Cell International ·Jiaxin Chen, Da Xu, Jianwei Cao, Li Zuo, Zhitao Han, Yijun Tian, Chuanmin Chu, Zhou Wang, Xiuwu Pan, Xingang Cui	28
11	Digestive system is a potential route of COVID-19: an analysis of single-cell coexpression pattern of key proteins in viral entry process 2020 ·Gut ·Hao Zhang, Zijian Kang, Haiyi Gong, Da Xu, Jing Wang, Zhixiu Li, Zifu Li, (unknown), Jianru Xiao, Jian Zhan, Tong Meng, Wang Zhou, Jianmin Liu, Huji Xu	329
12	<p>The Prognostic Comparison Between Hepatocellular Carcinoma with Portal Vein Tumor Thrombus and Bile Duct Cancer Thrombus After Liver Resection</p> 2020 ·Cancer Management and Research ·Xin Yang, Ying Zhu, Xia Zhao, Jianhua Li, Da Xu, Hu‐Liang Jia, Jubo Zhang	9
13	THBS1 facilitates colorectal liver metastasis through enhancing epithelial–mesenchymal transition 2020 ·Clinical & Translational Oncology ·Xiaofeng Liu, Da Xu, (unknown), (unknown), Chengfei Zhang, Yiyi Gong, Yang Jiang, Baocai Xing	46
14	The characteristics and long-term survival of patients with colorectal liver metastases with pathological complete response after chemotherapy 2020 ·Journal of Cancer ·Da Xu, Xiaoluan Yan, Jia-Ming Liu, Juan Li, Baocai Xing	9
15	Application of a hybrid model in predicting the incidence of tuberculosis in a Chinese population 2019 ·SHILAP Revista de lepidopterología ·(unknown), Zhiqiang Wang, Huai‐Dong Song, (unknown), He Bai, (unknown), (unknown), Da Xu, Jiarui Wang	1
16	Programmed death ligand 1 expression in human intrahepatic cholangiocarcinoma and its association with prognosis and CD8<sup>+</sup> T-cell immune responses 2018 ·Cancer Management and Research ·Ying Zhu, Xiangyu Wang, Yu Zhang, Da Xu, Jian Dong, Ze Zhang, Chenhe Yi, Hu‐Liang Jia, Xin Yang	47
17	The impact of primary tumour location in patients undergoing hepatic resection for colorectal liver metastasis 2018 ·European Journal of Surgical Oncology ·Kun Wang, Da Xu, Xiaoluan Yan, Graeme J. Poston, Baocai Xing	30
18	Genetic variation in the GSTM3 promoter confer risk and prognosis of renal cell carcinoma by reducing gene expression 2013 ·British Journal of Cancer ·Xiaojun Tan, Ying Wang, Yi Han, (unknown), Tong Su, Jian Hou, Da Xu, Yang Yu, Wenli Ma, Timothy C. Thompson, Guangwen Cao	22
19	Pharmacokinetics of Mycophenolic Acid and Estimation of Exposure Using Multiple Linear Regression Equations in Chinese Renal Allograft Recipients 2007 ·Clinical Pharmacokinetics ·Peijun Zhou, Da Xu, (unknown), Xianghui Wang, Kun Shao, Juping Zhao	21
20	Applied anatomy of rat kidney transplantation 2004 ·Da Xu	1

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact